Logo image of BXT.DE

BIONXT SOLUTIONS INC (BXT.DE) Stock Fundamental Analysis

FRA:BXT - Deutsche Boerse Ag - CA0909741062 - Common Stock - Currency: EUR

0.365  -0.01 (-1.88%)

Fundamental Rating

1

Overall BXT gets a fundamental rating of 1 out of 10. We evaluated BXT against 52 industry peers in the Pharmaceuticals industry. BXT may be in some trouble as it scores bad on both profitability and health. BXT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BXT has reported negative net income.
In the past year BXT has reported a negative cash flow from operations.
BXT.DE Yearly Net Income VS EBIT VS OCF VS FCFBXT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -905.32%, BXT is doing worse than 90.38% of the companies in the same industry.
Industry RankSector Rank
ROA -905.32%
ROE N/A
ROIC N/A
ROA(3y)-529.63%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BXT.DE Yearly ROA, ROE, ROICBXT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

BXT has a better Gross Margin (886.43%) than 100.00% of its industry peers.
BXT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 886.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BXT.DE Yearly Profit, Operating, Gross MarginsBXT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

0

2. Health

2.1 Basic Checks

BXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BXT has been increased compared to 1 year ago.
The debt/assets ratio for BXT is higher compared to a year ago.
BXT.DE Yearly Shares OutstandingBXT.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
BXT.DE Yearly Total Debt VS Total AssetsBXT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -149.72, we must say that BXT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -149.72, BXT is doing worse than 78.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -149.72
ROIC/WACCN/A
WACC8.57%
BXT.DE Yearly LT Debt VS Equity VS FCFBXT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 -5M -10M

2.3 Liquidity

A Current Ratio of 0.04 indicates that BXT may have some problems paying its short term obligations.
BXT has a Current ratio of 0.04. This is amonst the worse of the industry: BXT underperforms 90.38% of its industry peers.
BXT has a Quick Ratio of 0.04. This is a bad value and indicates that BXT is not financially healthy enough and could expect problems in meeting its short term obligations.
BXT has a worse Quick ratio (0.04) than 90.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
BXT.DE Yearly Current Assets VS Current LiabilitesBXT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.71% over the past year.
BXT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -89.20%.
BXT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.50% yearly.
EPS 1Y (TTM)55.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
Revenue 1Y (TTM)-89.2%
Revenue growth 3Y2.5%
Revenue growth 5YN/A
Sales Q2Q%200%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BXT.DE Yearly Revenue VS EstimatesBXT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 100K 200K 300K
BXT.DE Yearly EPS VS EstimatesBXT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BXT.DE Price Earnings VS Forward Price EarningsBXT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BXT.DE Per share dataBXT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BXT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONXT SOLUTIONS INC

FRA:BXT (3/7/2025, 7:00:00 PM)

0.365

-0.01 (-1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.03%
Ins Owner ChangeN/A
Market Cap41.39M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1534.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -905.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 886.43%
FCFM N/A
ROA(3y)-529.63%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -149.72
F-Score3
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)53.21%
Cap/Depr(5y)N/A
Cap/Sales(3y)71.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-89.2%
Revenue growth 3Y2.5%
Revenue growth 5YN/A
Sales Q2Q%200%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.05%
OCF growth 3YN/A
OCF growth 5YN/A